Possible role of α-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes

Diabetes Care

Volumn 30, Issue 10, 2007, Pages 2583-2587

  Tsuchiyama, Naomi ^a   Takamura, Toshinari ^a   Ando, Hitoshi ^a   Sakurai, Masaru ^a   Shimizu, Akiko ^a   Kato, Ken Ichiro ^a   Kurita, Seiichiro ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ARGININE; C PEPTIDE; GLUCAGON; INSULIN; METFORMIN; NATEGLINIDE; SULFONYLUREA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; FEMALE; GLUCAGON RELEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; AGED; AREA UNDER CURVE; ARGININE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; JAPAN; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 35148881128     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0066     Document Type: Article

References (26)

1. Consoli A: Role of liver in pathophysiology of NIDDM. Diabetes Care 15:430-441, 1992
2. Unger RH: Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 28:574-578, 1985
3. Aronoff SL, Bennett PH, Rushforth NB, Miller M, Unger RH: Arginine-stimulated hyperglucagonemia in diabetic Pima Indians. Diabetes 25:404-407, 1976
4. Aronoff SL, Bennett PH, Rushforth NB, Miller M, Unger RH: Normal glucagon response to arginine infusion in "prediabetic" Pima Indians. J Clin Endocrinol Metab 43:279-286, 1976
5. Unger RH: Glucagon physiology and pathophysiology. N Engl J Med 285:443-449, 1971
6. Unger RH: Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 27:1691-1709, 1978
7. Raskin P, Unger RH: Hyperglucagonemia and its suppression: importance in the metabolic control of diabetes. N Engl J Med 299:433-436, 1978
8. Petersen KF, Sullivan JT: Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018-2024, 2001
9. Jiang G, Zhang BB: Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284:E671-E678, 2003
10. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O: One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53:1187-1194, 2004
11. Raskin P, Aydin I, Unger RH: Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes. Diabetes 25:227-229, 1976
12. Gerich JE, Lorenzi M, Tsalikian E, Bohannon NV, Schneider V, Karam JH, Forsham PH: Effects of acute insulin withdrawal and administration on plasma glucagon responses to intravenous arginine in insulin-dependent subjects. Diabetes 25:955-960, 1976
13. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (Committee Report). Diabetes Care 26 (Suppl. 1):S5-S20, 2003
14. Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, Sugimoto T, Murase T, Kosaka K: Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16:780-788, 1993
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
16. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410, 2000
17. Takamura T, Sakurai M, Nakamura M, Shimizu A, Ota T, Misu H, Takeshita Y, Tsuchiyama N, Kurita S, Ando H, Kaneko S: Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes. Diabetes Res Clin Pract 75:278-284, 2007
18. Hamaguchi T, Fukushima H, Uehara M, Wada S, Shirotani T, Kishikawa H, Ichinose K, Yamaguchi K, Shichiri M: Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells. Diabetologia 34:801-806, 1991
19. Kalkhoff RK, Gossain VV, Matute ML: Plasma glucagon in obesity: response to arginine, glucose and protein administration. N Engl J Med 289:465-467, 1973
20. Gossain VV, Matute ML, Kalkhoff RK: Relative influence of obesity and diabetes on plasma alpha-cell glucagon. J Clin Endocrinol Metab 38:238-243, 1974
21. Larsson H, Ahren B: Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23:650-657, 2000
22. Palmer JP, Benson JW, Walter RM, Ensinck JW: Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects. J Clin Invest 58:565-570, 1976
23. Ahren B, Pacini G: Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 150:97-104, 2004
24. Robertson RP: Consequences on β-cell function and reserve after long-term pancreas transplantation. Diabetes 53:633-644, 2004
25. Sayama K, Imagawa A, Okita K, Uno S, Moriwaki M, Kozawa J, Iwahashi H, Yamagata K, Tamura S, Matsuzawa Y, Hanafusa T, Miyagawa J, Shimomura I: Pancreatic beta and alpha cells are both decreased in patients with fulminant type 1 diabetes: a morphometrical assessment. Diabetologia 48:1560-1564, 2005
26. Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebina Y, Wheeler MB, Braun M, Wang Q: Intraislet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab 3:47-58, 2006